The role of size in PEGylated liposomal doxorubicin biodistribution and anti‐tumour activity

The role of size in PEGylated liposomal doxorubicin biodistribution and anti‐tumour activity

Abstract The size of nanoliposome‐encapsulated drugs significantly affects their therapeutic efficacy, biodistribution, targeting ability, and toxicity profile for the cancer treatment. In the present study, the biodistribution and anti‐tumoral activity of PEGylated liposomal Doxorubicin (PLD) formu...

Full description

Saved in:

Bibliographic Details
Main Authors:	Saba Dadpour, Amin Mehrabian, Mahdieh Arabsalmani, Elaheh Mirhadi, Anis Askarizadeh, Mohammad Mashreghi, Mahmoud Reza Jaafari
Format:	Article
Language:	English
Published:	Wiley 2022-09-01
Series:	IET Nanobiotechnology
Subjects:	Biodistribution Cancer EPR effect Nanoparticle size PEGylated liposomal doxorubicin Therapeutic efficacy
Online Access:	https://doi.org/10.1049/nbt2.12094
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Efficacy and safety of pegylated liposomal doxorubicin and epirubicin as neoadjuvant chemotherapy for breast cancer
by: Yuanyuan Shen, et al.
Published: (2024-12-01)

Characterization and in vitro anticancer study of PEGylated liposome dually loaded with ferulic acid and doxorubicin
by: Andang Miatmoko, et al.
Published: (2025-01-01)

The supramolecular processing of liposomal doxorubicin hinders its therapeutic efficacy in cells
by: Annalisa Carretta, et al.
Published: (2024-09-01)

The comparison of biodistribution of glutathione PEGylated nanoliposomal doxorubicin formulations prepared by pre‐insertion and post‐insertion methods for brain delivery in normal mice
by: Amin Mehrabian, et al.
Published: (2023-04-01)

Preparation and Characterization of Hydrophobin 4-Coated Liposomes for Doxorubicin Delivery to Cancer Cells
by: Fatma Hande Osmanagaoglu, et al.
Published: (2024-10-01)

Biodistribution of intravenously delivered PEGylated carbon nanotubes to the rat brain cortex
by: Gisele Eva Bruch, et al.
Published: (2025-01-01)

A multicenter, randomized, open label, two formulation, crossover bioequivalence trial of doxorubicin hydrochloride liposomal injection in Chinese patients with metastatic breast cancer
by: Jingshu Wang, et al.
Published: (2025-01-01)

Synthesis and Characterization of PEGylated Liposomes and Nanostructured Lipid Carriers with Entrapped Bioactive Triterpenoids: Comparative Fingerprints and Quantification by UHPLC-QTOF-ESI<sup>+</sup>-MS, ATR-FTIR Spectroscopy, and HPLC-DAD
by: Carmen Socaciu, et al.
Published: (2024-12-01)

Doxorubicin-loaded PEGylated liposome modified with ANGPT2-specific peptide for integrative glioma-targeted imaging and therapy
by: Hongyan Li, et al.
Published: (2025-02-01)

Electrostatic properties of human germlines and biodistribution of small biologics
by: Leticia Maria De Souza Cordeiro, et al.
Published: (2024-12-01)

Acute Biodistribution Comparison of Fentanyl and Morphine
by: Rosamond Goodson, et al.
Published: (2024-09-01)

Preparation and Complex Characterisation of Stabilised Gold Nanoparticles: Biodistribution and Application for High Resolution In Vivo Imaging
by: Jaroslav Turánek, et al.
Published: (2024-11-01)

Iron(III)–Quercetin Complex: In Vivo Acute Toxicity and Biodistribution of Novel MRI Agent
by: Innuan P, et al.
Published: (2025-01-01)

PEGylation renders carnosine resistant to hydrolysis by serum carnosinase and increases renal carnosine levels
by: Shiqi Zhang, et al.
Published: (2024-07-01)

<i>In vitro</i> and <i>in vivo</i> tropism and biodistribution of recombinant simian adenovirus type 25
by: Irina V. Vavilova, et al.
Published: (2024-11-01)

Enhanced effect of the immunosuppressive soluble HLA-G2 homodimer by site-specific PEGylation
by: Chisato Yamada, et al.
Published: (2025-01-01)

Is Combined Bulevirtide and Pegylated Interferon Therapy for Chronic Hepatitis D Superior over Bulevirtide Monotherapy?
by: V. E. Syutkin, et al.
Published: (2020-09-01)

Bioactivities and Anti-Cancer Activities of NKT-Stimulatory Phenyl-Glycolipid Formulated with a PEGylated Lipid Nanocarrier
by: Hung JT, et al.
Published: (2024-11-01)

Potentiation of Doxorubicin Cytotoxicity Utilizing Clarithromycin Loaded-PEGylated Liposomes
by: Islam Alfreahat MS, et al.
Published: (2025-01-01)

Effect of Ionic and Nonionic Compounds Structure on the Fluidity of Model Lipid Membranes: Computer Simulation and EPR Experiment
by: Dariusz Man, et al.
Published: (2024-12-01)

Investigation of the efficacy of tyrosol on doxorubicin-induced acute cardiotoxicity in rats
by: Mustafa Cellat, et al.
Published: (2022-09-01)

Severe Lipoatrophy in a Growth Hormone Deficient Toddler Girl Treated with a Non-Pegylated Long-Acting Growth Hormone
by: Atilla Büyükgebiz, et al.
Published: (2025-01-01)

Effect of pimobendan on cytokine levels in doxorubicin-induced cardiotoxicity
by: Burak Dik, et al.

Exploring the Interaction of 3-Hydroxy-4-pyridinone Chelators with Liposome Membrane Models: Insights from DSC and EPR Analysis
by: Luísa M. P. F. Amaral, et al.
Published: (2024-12-01)

Comparative study of liposomes and liposomes-in-polymer hydrogel as transdermal carriers for improving the topical delivery of imperatorin
by: Junfeng BAN, et al.
Published: (2021-03-01)

Liposomal and Nanostructured Lipid Nanoformulations of a Pentacyclic Triterpenoid Birch Bark Extract: Structural Characterization and In Vitro Effects on Melanoma B16-F10 and Walker 256 Tumor Cells Apoptosis
by: Dumitriţa Rugină, et al.
Published: (2024-12-01)

Pegylated NIR Fluorophore-Conjugated OBHSA Prodrug for ERα-Targeted Theranostics with Enhanced Imaging and Long-Term Retention
by: Xiaohua Wang, et al.
Published: (2025-01-01)

Investigation of pharmacokinetics and immunogenicity of magnetosomes
by: M. Haripriyaa, et al.
Published: (2024-12-01)

Paclitaxel-Loaded, Pegylated Carboxylic Graphene Oxide with High Colloidal Stability, Sustained, pH-Responsive Release and Strong Anticancer Effects on Lung Cancer A549 Cell Line
by: Athina Angelopoulou, et al.
Published: (2024-11-01)

Streptomyces-derived nano-doxorubicin: Clinical status and patents granted
by: Kaur Prabhjot, et al.
Published: (2024-01-01)

Doxorubicin-induced cardiotoxicity: An update on the molecular mechanism, biomarkers and management
by: Mohd Amaan, et al.
Published: (2024-12-01)

Apigetrin ameliorates doxorubicin prompted testicular damage: biochemical, spermatological and histological based study
by: Muhammad Umar Ijaz, et al.
Published: (2024-04-01)

The role of circRNAs in resistance to doxorubicin
by: Mahla Sanati, et al.
Published: (2024-11-01)

Histopathological evaluation of the effects of thymoquinone and resveratrol on the liver in rats administered doxorubicin
by: Mehmet Burak Ates, et al.
Published: (2022-09-01)

Analysis of doxorubicin and fullerenol in rat serum by micellar electrokinetic capillary chromatography
by: Injac Rade, et al.
Published: (2024-09-01)

Stability study of oxaliplatin and doxorubicin for intraperitoneal administration with hyperthermia
by: V. Escudero-Ortiz, et al.
Published: (2014-05-01)

Innovative Approaches to Enhancing the Biomedical Properties of Liposomes
by: Ioana Lavinia Dejeu, et al.
Published: (2024-11-01)

Mitophagy in Doxorubicin-Induced Cardiotoxicity: Insights into Molecular Biology and Novel Therapeutic Strategies
by: Heng Zhang, et al.
Published: (2024-12-01)

Determination of protective effectiveness of nerium oleander distillation in doxorubicin-induced organ damages
by: Burak Dik, et al.

Titanium nanostructure mitigating doxorubicin–induced testicular toxicity in rats via regulating major autophagy signaling pathways
by: Rehab M. Abdel-Megeed, et al.
Published: (2025-06-01)